Word

Status

Pending

Status Code

730

Status Date

Tuesday, June 18, 2024

Serial Number

97771262

Mark Type

2

Filing Date

Friday, January 27, 2023

Published for Opposition

Tuesday, December 5, 2023

Trademark Owner History

Eli Lilly and Company - Owner At Publication

Classifications

5 Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

The mark consists of a small white square surrounded by a hazy pink sphere. The white background is not a feature of the mark.
The color(s) pink and white is/are claimed as a feature of the mark.

Trademark Events

Feb 15, 2023

New Application Office Supplied Data Entered

Jan 31, 2023

New Application Entered

Feb 16, 2023

Notice Of Design Search Code E-Mailed

Oct 25, 2023

Assigned To Examiner

Oct 30, 2023

Approved For Pub - Principal Register

Nov 15, 2023

Notification Of Notice Of Publication E-Mailed

Dec 5, 2023

Published For Opposition

Dec 5, 2023

Official Gazette Publication Confirmation E-Mailed

Jan 30, 2024

Noa E-Mailed - Sou Required From Applicant

Jun 18, 2024

Sou Teas Extension Received

Jun 18, 2024

Notice Of Approval Of Extension Request E-Mailed

Jun 18, 2024

Sou Extension 1 Filed

Jun 18, 2024

Sou Extension 1 Granted